§ The providers
Who sells what — and who to trust.

An independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.

View the provider overviewOverview & reviews
§ Learn
The educational layer, in progress.

Primers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.

View all Learn articles
503A + 503B · Southlake, TX

FarmaKeio: 503A + 503B compounder profile

A Texas bioidentical-hormone 503B outsourcing facility backed by a PCAB-accredited 503A custom-compounding network spanning HRT, weight loss, and sexual health.

Editorial independence

This profile is editorial. PeptideWellness has no commercial relationship with this pharmacy; coverage and assessment are never for sale.

FarmaKeio spans two entities: a 503B outsourcing facility (Farmakeio Outsourcing LLC, Southlake, TX) that publicly focuses on bioidentical hormone pellets, and a larger 503A custom-compounding network that carries the broader consumer menu.

Facility & accreditation

The 503B (Farmakeio Outsourcing LLC) is on the FDA Registered Outsourcing Facilities list [1], and its own page advertises patented bioidentical hormone pellets delivered to medical practices [2]. The 503A arm — “North American Custom Laboratories, LLC, dba FarmaKeio Superior Custom Compounding” — runs retail/compounding sites (Richardson, TX; Conway, AR; Albuquerque, NM) and says it is licensed in 49 states plus PR and USVI [2]. We independently confirmed PCAB accreditation for the 503A arm in ACHC’s own directory (listed as “North American Custom Labs / FarmaKeio,” Richardson, TX; PCAB Compounding Pharmacy) [3]. Additional badges on the site (IPS, A4PC) are memberships, not independently verified here. FarmaKeio’s 503A entity is also a named plaintiff in the outsourcing-industry (OFA) litigation over the GLP-1 shortage delistings.

What they compound

The 503B publicly advertises bioidentical hormone pellets [2]. The broader FarmaKeio network markets weight loss, hormone therapy, thyroid/adrenal, and sexual health to providers and patients [2]. Compounded GLP-1 (semaglutide/tirzepatide) is attributed to FarmaKeio by a third-party directory but is not stated on the company’s own 503B page, so we flag GLP-1 as unverified from a primary source.

Regulatory record

We found no FDA warning letter or untitled letter for FarmaKeio in public sources. The FDA 503B list shows the Southlake facility with an “Open” action status [1]. (A third-party directory reports a Form 483 around September 2025; we could not locate the FDA primary document, so we don’t assert it.) Dated to our review; status can change.

The read

One of the better-credentialed consumer-facing options here: the 503A arm is PCAB-accredited (independently confirmed via ACHC), the menu covers HRT and weight loss, and no FDA letter is on record. The main nuance is entity structure — the 503B publicly commits only to hormone pellets, so verify exactly which entity fills a given order.

References

  1. FDA — Registered Outsourcing Facilities (503B) list. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities (accessed 2026-07-01)
  2. FarmaKeio — official site (503B outsourcing + custom compounding). https://www.farmakeio.com/ (accessed 2026-07-01)
  3. ACHC / PCAB accredited-organization directory (listed as “North American Custom Labs / FarmaKeio,” Richardson, TX). https://organization.achc.org/ (accessed 2026-07-01)
§ The Daily

The peptide brief, delivered.

A 5-minute daily digest on peptide therapy news, provider updates, and regulatory changes.

Find your peptide Take 60-sec quiz